Facebook
Twitter
LinkedIn
Forward
Cervical Cancer: Etiology, Diagnosis, Treatment Options and Outcomes
Activity description
Cervical cancer remains a worldwide pandemic. In 2018, there were an estimated 570,000 new cases and 311,000 deaths worldwide, making it the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women. In low human development index settings, cervical cancer ranks second to breast cancer in incidence and mortality among women. During this educational activity, learners will become familiar with the etiology and diagnosis of cervical cancer and explore treatment options and outcomes for relapsed, recurrent and metastatic disease. Advances in current cervical cancer clinical research trials will also be addressed.
Provided by
This activity is provided by OptumHealth Education.
Commercial support
This activity is supported by an independent education grant from Seagen Inc. and Genmab.
Required hardware/software
Please ensure you are using the web-browser Chrome and disable any pop-up blocking software. Click here for information on how to enable pop-ups.
Target Audience
This activity is designed to meet the educational needs of case managers, counselors, educators, nurses, nurse practitioners, pharmacists, pharmacy technicians, PAs, physicians, psychologists, social workers, therapists and other health care providers (HCPs) who have an interest in cervical cancer.
Learning Objectives
At the end of this educational activity, participants should be able to:
- Discuss the etiology and diagnosis of cervical cancer
- Explore treatment options and outcomes for relapsed, recurrent or metastatic cervical cancer
- List advances in current cervical cancer clinical research trials
Additional Information
Presenter
Bradley J. Monk, MD, FACS, FACOG
Professor
Arizona Oncology (US Oncology Network)
US Oncology Medical Director of Gynecologic Oncology Research
University of Arizona College of Medicine – Phoenix
Creighton University School of Medicine at St. Joseph’s Hospital
Phoenix, Arizona
About the presenter
Dr. Bradley Monk graduated at the top of his class from the University of Arizona College of Medicine–Tucson in 1988 and completed a residency in obstetrics and gynecology at the University of California, Los Angeles, in 1992. Between 1988 and 1995, he was the recipient of three fellowships in medical genetics and gynecologic oncology. In 1995, Dr. Monk was appointed Director of Gynecologic Oncology at Texas Tech University Health Services Center and, from 1998 to 2010, was Associate Professor with Tenure of the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, at the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center and Director of Research in the Department of Obstetrics and Gynecology. Dr. Monk was then appointed Director and Professor in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. In 2016, he became a member of Arizona Oncology and part of the US Oncology Network, and he continues to practice in Phoenix. Most recently, he has been appointed the US Oncology Medical Director of Gynecologic Oncology Research. Dr. Monk is also a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine–Phoenix and works at Arizona Oncology (US Oncology Network). He has been named one of Arizona’s “Top Doctors” by PHOENIX magazine 5 years in a row beginning in 2012.
Dr. Monk’s research interests include the prevention and treatment of gynecologic cancers. He was the first to report the activity of anti-vascular endothelial growth factor (VEGF) therapy in ovarian cancer and his papers in the New England Journal of Medicine led to the global approval of anti-VEGF therapy and poly (ADP-ribose) polymerase (PARP) inhibitors in recurrent ovarian and cervical cancers in 2014. He was also the lead author on the pivotal trial of trabectedin in recurrent ovarian cancer as well as many other studies that have met their primary endpoints. Dr. Monk was awarded the highly prestigious Ernst Wertheim Award for his research in cervical cancer. He is on the Board of Directors for the GOG Foundation, Inc. and is the Cervical Cancer Chair for the Gynecologic Cancer Intergroup (GCIG). He is a past president of the Western Association of Gynecologic Oncologists (WAGO) and current co-director for the GOG Research Consortium (GOG-Partners).
Dr. Monk is a fellow of the American College of Surgeons (ACS), the American College of Obstetricians and Gynecologists (ACOG) and the American Society for Colposcopy and Cervical Pathology (ASCCP), as well as being an active member of the Society of Gynecologic Oncology (SGO), American Society of Clinical Oncology (ASCO) and other professional organizations. He has authored more than 300 peer-reviewed articles along with 31 book chapters dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and patient quality of life.
Activity planners
Sarah Chart, RN
Vice President
OptumHealth Education
Rebecca Gleason, RN
Clinical Activity Manager
OptumHealth Education
Disclosures of relevant financial relationships
In accordance with the ACCME Standards for Commercial SupportSM, OptumHealth Education (OHE) requires all those involved in the development of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or his/her spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest. OHE ensures that the content is independent of commercial bias.
Dr. Monk has disclosed that he serves as a consultant for Agenus, Akeso Bio, Iovance, Puma, AstraZeneca, Eisai, Elevar Therapeutics, Genmab/Seagen Inc., GOG Foundation, Merck, McKesson and Tesaro. He also serves on the Speakers’ Bureau for AstraZeneca, Eisai, Merck and Tesaro.
The activity planners have no financial relationships to disclose.
Method for calculating CE credit
CE credit was calculated by the complexity of content.
Accreditation statement
In support of improving patient care, this activity has been planned and implemented by OptumHealth Education. OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Credit designation statements
This activity was planned by and for the health care team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.
Nurses
The participant will be awarded up to 1.0 contact hour(s) of credit for attendance and completion of supplemental materials.
Nurse practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
Pharmacists/Pharmacy technicians
This activity is approved for 1.0 contact hours ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.00 contact hours.
Unique Activity Number(s): JA0007123-0000-21-309-H04-P/T
Physicians
OptumHealth Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PAs
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
Case Managers
This program has been submitted to The Commission for Case Manager Certification for approval to provide board-certified case managers with 1.0 contact hours.
Psychologists
OptumHealth Education is approved by the American Psychological Association (APA) to offer continuing education for psychologists. OptumHealth Education maintains responsibility for this program. 1.0 CE hours.
Social workers
As a Jointly Accredited Organization, OptumHealth Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. OptumHealth Education maintains responsibility for this course. Social workers completing this course receive 1.0 enduring continuing education credits.
Counselors and/or marriage and family therapists
CA: The Board of Behavioral Sciences has deferred CE course approvals to APA and ASWB for its licensees. See those approvals under Psychologists and Social Workers.
Other States: If your state is not specifically listed, nearly all state Counselor and MFT boards accept either APA or ASWB approval, or are reciprocal with other state licensing board approvals, such as those listed below. Check with your board to be sure.
Attendance
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization from which they wish to obtain credit.
Available Credit
- 1.00 ACPE - Pharmacists
- 1.00 ACPE - Pharmacy Technicians
- 1.00 AMA - Physicians
- 1.00 ANCC - Nurses
- 1.00 APA - Psychologists
- 1.00 Attendance - General Attendance
- 1.00 CCMC - General - Case Managers
You must be logged into your account to participate in this activity. Get started by clicking “Begin/Continue” and completing the “Pre-Activity Assessment”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. A complete listing of all of your activities can be found under “My Account”, “My Activities.”